¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ )Iu0MN&  
+9EG6"..@H  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© m5i?<Ko@  
->"Z1  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© O7DaVlln  
d2'1 6.lV  
1.Co-stimulators (or co-stimulating molecules) j _]#Ew\q  
3i\<#{  
2.NK-kB ,%Go.3i[  
lqaOLZH  
3.Immunoglobulin superfamily nulLK28q  
7 LotN6H  
4.antigen-presenting cell (APC) P|U9f6^3  
2 Q bCH}  
5.death domain * I)F5M  
/Py1Q  
6.CCR and CXCR >~+qU&'2  
WR :I2-1  
7.Lectin (or mitogen) )#%v1rR  
OV>JmYe1{/  
8.Clusters of differentiation, CD) 5EX Ghc'  
yq6Gyoi<  
9.B7 family m7 $t$/g  
Ea<kc[Q  
10.Cytotoxic T lymphocyte, CTL) B!j7vXM2  
;N(9n X}%)  
11.IL-15 and IL-15 receptor (IL-15R) U*Sjb% Qb  
cqd}.D  
12.MHC restriction z%lLbKSe  
(q yT,K8  
13.Affinity-chromatography BJ*8mKi h  
+3d.JQoKl  
14.Cyctosprin A, CsA goje4;  
Ge_Gx*R  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) %=*nJvYS  
&P:2`\'  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 5 fDp"-  
han S8  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 cOoF +hz0O  
o,yZ1"  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ @AfC$T  
h8 !(WO!  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ i5; _  
/r?EY &9G  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© f=cj5T:[  
XCyAt;neon  
ÃâÒßѧרҵ£º  /oC@:7  
=u<jxV9  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ ]yV,lp  
[J\! 2\Oo  
Ïû»¯ÄÚ¿Æ£º "?Yf3G:\0  
S]g`Ds<  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ b FB.hkTP  
ojbms>a  
ѪҺ²¡Ñ§×¨Òµ£º z;lWr(-x  
N?l  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»